This finding significantly expands the functional spectrum of FGFR1, as existing literature primarily documents the role of the cGMP-PKG pathway in prostate cancer, ovarian cancer, and other malignancies (48, 49), while its regulatory mechanisms in BLCA remain an emerging field of research. This evidence concerns the gene FGFR1 and prostate carcinoma.